Enlivex Ltd.

ENLV Healthcare Biotechnology

In the quarter to June 2026, EPS grew 5,185.1% and free cash flow grew 35.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

0.21 0.01 −4.55%
Market cap
$4.5M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jun '26 Dec '25 Sep '25 Jun '25 Older periods
Current Ratio
119.39 193.24 6.43 6.41

+8 more quarters

Net Debt/EBITDA
881.46 300.51 7.35 6.52
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow per Share
0.00 (0.86) (1.24) (0.76)
Book value per Share
235.67 634.85 10.90 11.98
Free Cash Flow
— (2.63) (1.99) (1.20)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Oct 2026